Please Wait...

Development of two polyclonal antibodies against the human periostin (PN) and analysis of their specificities in serum by Western blot (WB) and in bone by immunohistochemistry (IHC)

Vergnaud P, Pagnon A, Bertholon C, Lhoste Y, Chassaing E, Borel O, Gineyts E, Schubert T, Clezardin P, Chapurlat R, Rousseau JCh

PURPOSE

Periostin belongs to the matricellular family of proteins and is mainly expressed in the periosteum. However, several authors have suggested roles for PN inside the cells: regulation of Notch1 expression (Tanabe, 2010), regulation of cell invasiveness (Isono, 2009) and activation of lysyl-oxydase (Kudo, 2011). The aims of this study were to develop two polyclonal antibodies against the Fas-1 region of human PN and investigate what they recognize in human serum and bone.

METHODS

By in silico study of the human PN we have detected two sequences of amino acids suitable for generate antibodies (Patent n° 13/375,870) in the second Fasciclin-like domain (ETLEGNTIEIGCDGDSI, Ab-34) and in the fourth Fasciclin-like domain (CKGFEPGVTNILKTTQGSK, Ab-12). These two peptides were injected in rabbits for immunization following a standard protocol of 12 weeks. Specific polyclonal antibodies Ab12 and Ab34 were purified by immunoaffinity. We assessed the specificity of these antibodies for PN by IHC in human bone tissue and by WB analysis in human sera previously depleted for albumin, IgG and transferrin.

RESULTS

In bone as in serum Ab-12 and Ab-34 antibodies did not have the same pattern of recognition. WB analysis showed that in non-reducing conditions Ab-12 recognized two bands, a high molecular band around 200 kDa and a second one at 75 kDa. After serum reduction by dithiothreitol, these bands disappeared and 3 bands were detected at 70, 50 and 25 kDa. On the other hand, Ab-34 recognized in non-reducing conditions only one band at 75 kDa. After reduction, the band at 75 kDa migrates slightly higher at 100 kDa suggesting that the reduction of intra-chain disulfide bridges leads to a more extended conformation of this PN form and makes it run more slowly on gel. By IHC, we showed that Ab-12 stained the cytoplasm of osteoblasts located at the interface between cortical bone and bone marrow and the cytoplasm of osteoblasts present in the Havers canals. On the contrary, Ab-34 has a matrix staining in the periosteum and in the Havers canals.

CONCLUSIONS

We have generated two polyclonal antibodies against the Fas-like domains of human PN. Our preliminary results suggest that they highlighted in serum and in bone at least two forms of PN molecules.

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

Still time to catch up on summer reading on recent developments in #Alzheimer's Disease Fluid Biomarkers here int t… https://t.co/kyQmz7FxlN
bioclinica (3 days ago)
Our clients have substantial success w #eSource, some spanning well over a decade. Still other organizations remain… https://t.co/UwVs6ajPp4
bioclinica (4 days ago)
Our clients have substantial success w #eSource, some spanning well over a decade. Still some in the industry remai… https://t.co/ASuUvN6xb9
bioclinica (6 days ago)
RT @RfwrightLSL: When Do You Think #BYOD (Bring Your Own Device) Will Become Widely Used To Capture PRO Data In #Clinical #Research? https:…
bioclinica (2 weeks ago)
ICYMI: Our V.P./Head of Neuroscience & Cardiovascular Svcs., Dr. Joyce Suhy, talks about challenges in determining… https://t.co/Lns6B3VPPN
bioclinica (2 weeks ago)
RT @FCR_News_Today: FDA Issues New Guides on Use of Electronic Health Information in #ClinicalTrials. #ClinicalResearch https://t.co/j8LHV2…
bioclinica (2 weeks ago)

Latest Blogs:

Latin America: Benefit from the Right Partner
Removing Risk from Clinical Trial Management System (CTMS) Implementations
Collaboration Between Clinical Operations and the Logistics and Supply Chain Teams is Key to Trial Success
The Value of Protocol Review
CTMS and RBM: Hot Topics at OCT Nordics in Copenhagen